The agency takes its time – particularly with diagnostics.
Whether sitting on a pile of cash or guarding against growing pressures, acquisitions are the answer.
Big-cap device makers on European exchanges did nicely in 2021, whereas their US-listed brethren had a harder time.
The FDA scrambles for more rapid Covid-19 tests, and the device sector enjoys a late flurry of deals.
Roche, its coffers full from coronavirus test sales, ups its research spending – but Baxter cuts back.
Diagnostics companies enjoy notable uplift in sales; elsewhere, spinouts could shape the future.
Staffing levels changed little across 2020 as M&A slowed – but sales are another story.